Skip to main content
Luoxin Pharmaceuticals Group Stock Co., Ltd. logo

Luoxin Pharmaceuticals Group Stock Co., Ltd. — Investor Relations & Filings

Ticker · 002793 ISIN · CNE1000026S7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,601 across all filing types
Latest filing 2025-10-27 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002793

About Luoxin Pharmaceuticals Group Stock Co., Ltd.

https://www.luoxin.cn

Luoxin Pharmaceuticals Group Stock Co., Ltd. focuses on the research, development, manufacturing, and distribution of diverse medicinal products. The company specializes in therapeutic areas including digestive health, respiratory medicine, anti-infectives, and oncology. Its portfolio includes various formulations such as injections, tablets, and capsules, with a notable emphasis on proton pump inhibitors and respiratory treatments. Luoxin operates a vertically integrated model, producing both active pharmaceutical ingredients (APIs) and finished dosage forms. The organization emphasizes innovation through dedicated R&D facilities to develop high-quality healthcare solutions. Its operations are supported by a comprehensive supply chain and manufacturing infrastructure designed to adhere to international quality standards, serving broad market segments with a focus on clinical efficacy and patient accessibility.

Recent filings

Filing Released Lang Actions
董事会议事规则（2025年10月）
Governance Information Classification · 100% confidence The document is titled "董事会议事规则" which translates to "Rules of Procedure for the Board of Directors" of 罗欣药业集团股份有限公司. It details the structure, duties, responsibilities, meeting procedures, and governance rules of the company's board of directors. It references relevant laws and regulations governing board conduct and decision-making. There is no financial data, earnings information, or report publication mentioned. The content is focused on governance practices and internal rules of the board. Therefore, this document fits the category of Governance Information (CGR). The document length is substantial and contains detailed governance rules, not just an announcement or summary.
2025-10-27 Chinese
关于召开2025年第六次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2025 sixth extraordinary general meeting (临时股东会) of Luoxin Pharmaceutical Group Co., Ltd. It includes information about the meeting time, location, voting procedures, agenda items, and proxy forms. The content focuses on the announcement and procedural details for the shareholders' meeting, including proposals to be voted on, but does not contain any voting results or financial statements. It is not a report of voting results, nor a financial report or management discussion. The document is a formal meeting notice and proxy solicitation for shareholders to participate in the meeting and vote on proposals. Therefore, it fits best into the category of Proxy Solicitation & Information Statement (PSI).
2025-10-27 Chinese
第五届董事会第三十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the 32nd meeting of the 5th Board of Directors of Luoxin Pharmaceutical Group Co., Ltd. It includes details about the meeting date, attendance, and voting results on various agenda items such as approval of the 2025 Q3 report, amendments to the company charter and board rules, non-recurring gains and losses report, previous fundraising usage report, and the scheduling of an extraordinary shareholders meeting. The document references other reports and materials published elsewhere (e.g., on cninfo.com.cn) but does not contain the full reports themselves. The focus is on board meeting decisions and governance matters, including changes to board size and procedural rules. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management. The document is not a full financial report, audit report, or shareholder meeting materials, but a formal board meeting resolution announcement.
2025-10-27 Chinese
关于选举职工代表董事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election of an employee representative director to the company's board. It includes details about the elected individual, their qualifications, and compliance with relevant laws and company rules. There is no financial data, no mention of annual or quarterly reports, no audit information, and no indication of a meeting presentation or voting results announcement. The content focuses on board/management information, specifically the appointment of a board member. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification, so those categories are excluded.
2025-10-15 Chinese
2025年第五次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the resolutions passed at the 2025 fifth extraordinary general meeting of shareholders of Luoxin Pharmaceutical Group Co., Ltd. It details the meeting's basic information, attendance, voting results on various proposals, and legal opinions on the meeting's validity. The document does not contain financial statements or detailed financial analysis but reports the official voting results and meeting outcomes. It is not a full annual or interim report, nor a management discussion or earnings release. The document fits the definition of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports shareholder vote results at a general meeting.
2025-10-15 Chinese
北京市金杜律师事务所上海分所关于罗欣药业集团股份有限公司2025年第五次临时股东大会之法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, procedures, attendance, and voting results of a specific shareholders' meeting (the 2025 fifth extraordinary general meeting) of a company. It details the legal compliance of the meeting's call, attendance, and voting process, and confirms the validity of the resolutions passed. The document does not contain financial statements or financial performance data, nor is it a report of financial results or management discussion. It is not an announcement of voting results in a brief form but a detailed legal opinion on the meeting's legality and procedures. This type of document is best classified as a Declaration of Voting Results & Voting Rights Announcements (DVA), as it relates to official voting results and legal validation of a shareholders' meeting.
2025-10-15 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.